AI Drugmaker BioXcel Beats Investor Fraud Suit, For Now
By Rae Ann Varona · July 12, 2024, 10:57 PM EDT
A Connecticut federal judge has tossed a proposed securities fraud class action against BioXcel Therapeutics Inc., saying that while shareholders sufficiently alleged the AI-driven drugmaker made misleading statements concerning a dementia...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login